Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
"His fiancee gave birth this morning, of all mornings! We were scared because we've got Glastonbury tonight", said co-singer Chloe Rhodes.
Festival-goers have been enjoying the second day of the Glastonbury festival.
Soros says that the European Union will struggle through the process of Brexit, with other countries wishing to follow suit.